A study led by researchers from IBEC and IDIBAPS achieves, for the first time, the control of brain state transitions using a molecule responsive to light, named PAI. The results not only pave the way to act on the brain patterns activity, but they also could lead to the development of photomodulated drugs for the treatment of brain lesions or diseases such as depression, bipolar disorders or Parkinson’s or Alzheimer’s diseases.
With a new method that combines high-powered scanning force microscopes and machine learning, IBEC researchers have drastically reduced the processing time required to achieve nanoscale biochemical compositions map from electric images of eukaryotic cells in just seconds. Using earlier computation methods, processing one image could take even months.
The company Depuración de Aguas del Mediterráneo (DAM) and the Institute for Bioengineering of Catalonia (IBEC) develop a system equipped with chemical sensors that provides information, in real time, on the intensity and location of odor sources in the Waste Water Treatment Plants (WWTP). The system has been calibrated and validated under real operating conditions through several measurement campaigns at the Molina de Segura WWTP (Murcia).
Researchers from IBEC, in collaboration with an international team, describe the first molecules capable of regulate glycine receptors with light: Glyght and Azo-NZ1. The new molecules are a promising way to study neuronal circuits, to develop drug-based phototherapies non-invasively, and to understand neurological disorders related with the incorrect functioning of glycine receptors, as hyperekplexia, epilepsy and autism.
An international team led by SPECS Lab at the Institute for Bioengineering of Catalonia (IBEC) reveals how the brain improves through self-supervised learning combining an analysis of over three decades of research in neuroscience and artificial intelligence.
IBEC researchers led by Javier Ramón and Juan M. Fernández develop the first three-dimensional model for myotonic dystrophy, a rare disease that currently has no cure. The model combines patient cells and bioengineering techniques and represents a major advance over the use of animals and cell cultures. This new model will help in the design of personalized and more effective treatments, and for drug testing in a much more efficient way.
The accumulation of abnormal glycogen in glial cells of the nervous system causes inflammation and degeneration of the brain. The study, led by IRB Barcelona and with contribution of Arnau Hervera and Jose Antonio del Río from IBEC, has been recently published in the journal Brain.
Researchers at the Institute for Bioengineering of Catalonia (IBEC) led by Samuel Sánchez achieve a breakthrough in the field of biological robots by developing new biobots based on muscle cells that can swim at unprecedented velocities.
A comprehensive review led by IBEC researchers from the “Bacterial infections: antimicrobial therapies” group highlights the clinical relevance of the bacterium Pseudomonas aeruginosa and its presence in bacterial biofilms.
A team of researchers led by Raimon Jané from IBEC, together with international partners at imec in the Netherlands and a Hospital in Belgium, develops an innovative procedure to evaluate pulmonary diseases.